Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Hereditary Sensory and Autonomic Neuropathies 3Endometrial Neoplasms 3Neoplasms 2Breast Neoplasms 2Advanced Solid Tumor 2Triple Negative Breast Neoplasms 1Neoplasm Metastasis 1Lung Neoplasms 1Head and Neck Neoplasms 1Genital Diseases 1Colonic Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Endometrioid 1Advanced Nonhematologic Malignancies 1

Interventions

sapanisertib 2MLN 8237 2tovorafenib 1serabelisib 1pevonedistat 1TAK 733 1Paclitaxel 1Irinotecan 1Cetuximab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Advanced Nonhematologic Malignancies × serabelisib × Clear all
NCT01899053 2019-10-30

A Safety and Pharmacokinetic Study of TAK-228 in Combination With TAK-117 in Adult Participants With Advanced Nonhematologic Malignancies

Takeda

Phase 1 Completed
101 enrolled 54 charts

Advanced Nonhematologic Malignancies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡